Lidocaine 1.8% + Placebo
ApprovedCompleted 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Carpal Tunnel Syndrome
Conditions
Carpal Tunnel Syndrome
Trial Timeline
Feb 24, 2020 → May 7, 2023
NCT ID
NCT04245371About Lidocaine 1.8% + Placebo
Lidocaine 1.8% + Placebo is a approved stage product being developed by Scilex Holding for Carpal Tunnel Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT04245371. Target conditions include Carpal Tunnel Syndrome.
What happened to similar drugs?
0 of 1 similar drugs in Carpal Tunnel Syndrome were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
20
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04245371 | Approved | Completed |
Competing Products
1 competing product in Carpal Tunnel Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Gabapentin | Pfizer | Phase 3 | 40 |